Download this complimentary Expert Insights eBook today, including an interview with a leading expert in the field!
Ready to move beyond the biological and manufacturing barriers holding back ADC development? This Expert Insights eBook equips scientists with comprehensive strategies for rational payload design, streamlined one-pot synthesis, and rigorous analytical characterization — accelerating the next generation of precision oncology therapeutics from concept to clinic.
Key Learning Points:
- Machine learning can rationally design optimized cytotoxic payloads with enhanced bystander effects to target antigen-heterogeneous tumors
- One-pot synthesis enables direct ADC preparation from unpurified antibodies, dramatically simplifying manufacturing workflows and reducing production time from days to approximately two hours
- Advanced peptide mapping with high-resolution mass spectrometry provides precise site-specific characterization — identifying 26 conjugation sites in a lysine-linked ADC with exceptional mass accuracy and reproducibility — essential for quality control
- Integration of computational design, process engineering, and analytical precision accelerates next-generation ADC development
- Leading ADC researcher Prof. Kyoji Tsuchikama (UTHealth Houston) shares expert perspectives on dual-drug platforms, novel linker technologies, and the future of AI-guided ADC design
Click ‘LOOK INSIDE’ to download the PDF now.
More Information
Antibody-drug conjugates (ADCs) represent a precision medicine breakthrough in cancer therapy, combining the targeting specificity of monoclonal antibodies with potent cytotoxic drugs. This three-component system — antibody, linker, and payload — delivers chemotherapy directly to tumor cells while minimizing systemic toxicity. Despite over 15 FDA-approved ADCs showing clinical success, two critical challenges remain: tumor heterogeneity, where variable antigen expression limits efficacy, and complex manufacturing processes that increase costs and development timelines. This eBook presents innovations addressing both challenges through AI-guided payload design for enhanced bystander killing, streamlined one-pot synthesis, and advanced analytical characterization methods. An exclusive interview with Prof. Kyoji Tsuchikama, Associate Professor and Barbara and Peer Boedeker Professor in Cancer Research at UTHealth Houston, further explores the cutting edge of ADC linker chemistry, dual-payload conjugation platforms, and the growing role of AI in rational ADC design.
Articles contained in the collection:
- Guo, Y. et al. (2024). Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors. Advanced Science. https://doi.org/10.1002/advs.202306309.
- Lu, M. et al. (2025). Direct Preparation of Site-Specific Antibody-Drug Conjugates with Unpurified Antibodies in Culture Medium. Chembiochem. https://doi.org/10.1002/cbic.202401082.
- Identification of Conjugation Sites in an Antibody-Drug Conjugate — Application note by Agilent Technologies.
- Advancing Antibody-Drug Conjugates — Interview with Prof. Kyoji Tsuchikama, UTHealth Houston.
Brought to you by
Sponsored by
